Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson's Disease.
Acetates
/ therapeutic use
Anti-Inflammatory Agents
/ therapeutic use
Astrocytes
/ metabolism
Cyclopropanes
/ therapeutic use
Humans
Inflammation
/ drug therapy
Leukotriene Antagonists
/ therapeutic use
Lewy Bodies
/ metabolism
Microglia
/ metabolism
Parkinson Disease
/ drug therapy
Quinolines
/ therapeutic use
Receptors, Leukotriene
/ metabolism
Sulfides
/ therapeutic use
Parkinson’s disease
alpha-synuclein
leukotriene
microglia
montelukast
neuroinflammation
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
25 May 2021
25 May 2021
Historique:
received:
23
04
2021
revised:
16
05
2021
accepted:
21
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
22
6
2021
Statut:
epublish
Résumé
Parkinson's disease (PD) is a neurodegenerative disorder where misfolded alpha-synuclein-enriched aggregates called Lewy bodies are central in pathogenesis. No neuroprotective or disease-modifying treatments are currently available. Parkinson's disease is considered a multifactorial disease and evidence from multiple patient studies and animal models has shown a significant immune component during the course of the disease, highlighting immunomodulation as a potential treatment strategy. The immune changes occur centrally, involving microglia and astrocytes but also peripherally with changes to the innate and adaptive immune system. Here, we review current understanding of different components of the PD immune response with a particular emphasis on the leukotriene pathway. We will also describe evidence of montelukast, a leukotriene receptor antagonist, as a possible anti-inflammatory treatment for PD.
Identifiants
pubmed: 34070609
pii: ijms22115606
doi: 10.3390/ijms22115606
pmc: PMC8198163
pii:
doi:
Substances chimiques
Acetates
0
Anti-Inflammatory Agents
0
Cyclopropanes
0
Leukotriene Antagonists
0
Quinolines
0
Receptors, Leukotriene
0
Sulfides
0
montelukast
MHM278SD3E
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Axel and Margaret Ax:son Johnsons foundation
ID : 2019
Références
Arch Pharm Res. 2019 May;42(5):416-425
pubmed: 30830660
Brain Behav Immun. 2019 Oct;81:41-51
pubmed: 31271873
Neurochem Int. 2014 Sep;75:26-31
pubmed: 24879954
Cell Stem Cell. 2018 Jul 05;23(1):123-131.e6
pubmed: 29979986
JAMA Neurol. 2017 Jul 1;74(7):780-792
pubmed: 28586827
Neuroscience. 2013 Jan 3;228:73-82
pubmed: 23079635
Brain Behav Immun. 2020 Jul;87:473-488
pubmed: 32006615
J Neurochem. 2007 Nov;103(4):1310-8
pubmed: 17711426
Neuroscience. 2015 Aug 27;302:89-102
pubmed: 25450953
CNS Neurosci Ther. 2016 Dec;22(12):943-951
pubmed: 27542570
J Neurol Neurosurg Psychiatry. 2010 Aug;81(8):890-1
pubmed: 20462916
Ann Clin Transl Neurol. 2016 Nov 04;3(12):924-933
pubmed: 28097204
J Cereb Blood Flow Metab. 2018 Feb;38(2):204-224
pubmed: 29256293
Lancet Neurol. 2009 Apr;8(4):382-97
pubmed: 19296921
Front Immunol. 2015 Aug 17;6:423
pubmed: 26347746
Adv Exp Med Biol. 2019;1175:335-353
pubmed: 31583594
Neuroscience. 2006 Jul 7;140(3):969-79
pubmed: 16650938
Alzheimers Res Ther. 2014 Jan 02;6(1):1
pubmed: 24382028
Front Immunol. 2018 Sep 19;9:2122
pubmed: 30283455
Eur J Pharmacol. 2019 Jan 5;842:208-220
pubmed: 30389631
Curr Neurol Neurosci Rep. 2019 Apr 2;19(5):24
pubmed: 30941587
Nat Commun. 2015 Oct 27;6:8466
pubmed: 26506265
J Parkinsons Dis. 2019;9(4):705-709
pubmed: 31524180
Neuroscience. 2011 Aug 25;189:1-11
pubmed: 21664436
Eur J Pharmacol. 2018 Jan 15;819:30-34
pubmed: 29183836
Neurosci Lett. 2003 May 1;341(2):87-90
pubmed: 12686372
Int Immunol. 2019 Aug 23;31(9):607-615
pubmed: 31135881
Mol Neurobiol. 2018 Mar;55(3):2403-2419
pubmed: 28357809
J Allergy Clin Immunol. 1996 Sep;98(3):528-34
pubmed: 8828530
Neuroreport. 2017 Mar 22;28(5):242-249
pubmed: 28178069
J Parkinsons Dis. 2013;3(4):493-514
pubmed: 24275605
Glia. 2019 Oct;67(10):1821-1841
pubmed: 31033014
Neurotherapeutics. 2020 Jul;17(3):1061-1074
pubmed: 32072462
Am J Ther. 1998 May;5(3):189-95
pubmed: 10099058
Brain Behav Immun. 2019 Feb;76:236-247
pubmed: 30550933
Nature. 1999 Jun 24;399(6738):789-93
pubmed: 10391245
Trends Pharmacol Sci. 2006 Jul;27(7):384-90
pubmed: 16766048
Curr Pharm Des. 2016;22(5):541-8
pubmed: 26601965
JAMA Neurol. 2018 Aug 1;75(8):939-946
pubmed: 29710331
Ann Clin Transl Neurol. 2018 May 31;5(7):870-875
pubmed: 30009205
Curr Opin Neurol. 2019 Aug;32(4):597-603
pubmed: 31145128
Int J Mol Sci. 2017 May 05;18(5):
pubmed: 28475165
Mov Disord. 2021 Jan;36(1):25-36
pubmed: 33314312
Prog Neurobiol. 2018 Oct;169:1-23
pubmed: 30114440
Int Immunopharmacol. 2020 Jan;78:105947
pubmed: 31796384
Chem Rev. 2011 Oct 12;111(10):5866-98
pubmed: 21936577
J Neuroinflammation. 2021 Jan 5;18(1):4
pubmed: 33402167
J Clin Invest. 2009 Jan;119(1):182-92
pubmed: 19104149
Neurobiol Aging. 2020 Mar;87:1-10
pubmed: 31986345
Mov Disord. 2015 Oct;30(12):1600-11
pubmed: 26474317
Neurology. 2007 Jan 30;68(5):384-6
pubmed: 17082464
Lancet. 2015 Aug 29;386(9996):896-912
pubmed: 25904081
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
Clin Case Rep. 2015 Jul;3(7):635-7
pubmed: 26273459
Adv Exp Med Biol. 2019;1175:149-179
pubmed: 31583588
Open Neurol J. 2017 Jan 31;11:7-10
pubmed: 28567133
Bioorg Med Chem. 2019 Sep 1;27(17):3745-3759
pubmed: 31331653
Glia. 2013 Mar;61(3):349-60
pubmed: 23108585
Brain. 2015 Sep;138(Pt 9):2687-700
pubmed: 26137956
Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):367-375
pubmed: 30270409
Science. 1983 May 6;220(4597):568-75
pubmed: 6301011
Trends Neurosci. 2017 Jun;40(6):358-370
pubmed: 28527591
Mov Disord. 2021 Jan;36(1):16-24
pubmed: 32357266
Microorganisms. 2020 May 02;8(5):
pubmed: 32370298
J Neurol Sci. 2017 Oct 15;381:308-314
pubmed: 28991704
Mediators Inflamm. 2017;2017:3454212
pubmed: 28607533
Neuropharmacology. 2013 Oct;73:380-7
pubmed: 23800665
Expert Rev Respir Med. 2019 Dec;13(12):1169-1178
pubmed: 31544544
Mov Disord. 2016 Feb;31(2):178-92
pubmed: 26813776
BMJ Open. 2020 Nov 23;10(11):e040527
pubmed: 33234645
Int J Clin Pharm. 2020 Oct 9;:
pubmed: 33034810
Ann Neurol. 2016 Jun;79(6):940-9
pubmed: 27015771
Front Cell Neurosci. 2018 Nov 15;12:401
pubmed: 30524236
Neurosci Lett. 2018 Aug 24;682:100-105
pubmed: 29885451
Int J Neurosci. 2015;125(10):717-25
pubmed: 25364880
Brain Res. 2014 Jul 14;1572:59-71
pubmed: 24858057
Nat Commun. 2020 Apr 20;11(1):1875
pubmed: 32313102
Immunology. 2018 Jun;154(2):204-219
pubmed: 29513402
Front Mol Biosci. 2020 Dec 17;7:610132
pubmed: 33392263
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2013 Jan;42(1):52-60
pubmed: 23505108
Proc Natl Acad Sci U S A. 2021 Mar 9;118(10):
pubmed: 33658371
Toxicol Appl Pharmacol. 2018 Nov 1;358:76-85
pubmed: 30222980
Br J Pharmacol. 2014 Aug;171(15):3551-74
pubmed: 24588652
Neurol Sci. 2019 Jan;40(1):113-120
pubmed: 30315378
Neurogenetics. 2008 Feb;9(1):1-13
pubmed: 18196299
Adv Exp Med Biol. 2019;1175:45-91
pubmed: 31583584
Mov Disord. 2018 Aug;33(8):1248-1266
pubmed: 29570866
Drug Discov Today. 2019 Feb;24(2):505-516
pubmed: 30240876
Neurotoxicology. 2017 Jul;61:132-141
pubmed: 27058967
Int J Mol Sci. 2019 Sep 14;20(18):
pubmed: 31540057
Neurosci Lett. 2007 Jan 22;412(1):78-83
pubmed: 17196746
J Alzheimers Dis. 2018;62(3):1337-1344
pubmed: 29254095
Nat Neurosci. 2011 Aug 26;14(9):1098-100
pubmed: 21878923
Brain Behav Immun. 2020 Aug;88:844-855
pubmed: 32222525
Cochrane Database Syst Rev. 2011 Nov 09;(11):CD008454
pubmed: 22071848
Lancet Neurol. 2017 Oct;16(10):789-796
pubmed: 28684245